Clinical Pharmacokinetics

, Volume 25, Issue 4, pp 329–341 | Cite as

Pharmacokinetic Optimisation of Oral Antifungal Therapy

  • Monika Schäfer-Korting
Review Article Pharmacokinetics-Therapeutics


The range of oral antifungal therapy has been expanded recently by the introduction of itraconazole, fluconazole and terbinaflne. These agents have a broader spectrum of activity than griseofulvin and flucytosine, and induce less liver toxicity than ketoconazole. Treatment with these agents may be optimised by application of pharmacokinetic principles.

Griseofulvin, ketoconazole and itraconazole should be administered with food to ensure adequate absorption. Maximal absorption of griseofulvin is achieved by administration of the drug as a solid solution in polyethylene glycol. Absorption of azole antifungal agents is impaired by high gastric pH, which is observed in some patients with acquired immunodeficiency syndrome. It is also impaired by frequent vomiting, which commonly occurs in patients with neutropenia. Furthermore, antacids, H2-antagonists and sucralfate interfere with absorption of ketoconazole.

The newer oral antifungals are more slowly eliminated and associated with less pronounced drug interactions than ketoconazole. As with ketoconazole, itraconazole and fluconazole influence cyclosporin metabolism. These effects are of clinical relevance and necessitate cyclosporin dosage reduction. However, the cyclosporin dosage reduction required during coadministration of itraconazole and fluconazole (50 to 55%) is less than that required when ketoconazole is concomitantly administered (85%). Monitoring of cyclosporin concentrations during coadministration with these agents is necessary to avoid nephrotoxicity. Drug monitoring is also advisable when phenytoin, carbamazepine or rifampicin (rifampin) are administered concomitantly with azoles, due to a mutual influence on drug metabolism.

The antifungal activity of itraconazole is not related exclusively to free drug concentrations. Therefore, the low protein binding of fluconazole does not place this agent at an advantage over itraconazole in the treatment of fungal meningitis. However, terbinafine may be superior to itraconazole for the treatment of tinea unguium, another recalcitrant fungal disease, because terbinafine more rapidly penetrates the nail plate. During repeated use, itraconazole concentrations increase slowly in the nail plate. Steady-state concentrations are reached in the stratum corneum only after several weeks’ administration. Following cessation of treatment, terbinafine, itraconazole and ketoconazole concentrations in keratinised tissues decline slowly. This allows a short duration of drug treatment.

Some clinical trials suggest that low concentrations of flucytosine, griseofulvin and itraconazole are associated with treatment failure. Flucytosine-induced myelotoxicity also appears to be concentration dependent. This adverse reaction may be caused by fluorouracil (which is produced by metabolism of flucytosine by enterobacillary flora in the gut) rather than by the parent compound.


Fluconazole Itraconazole Ketoconazole Azole Terbinafine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinylestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. British Journal of Clinical Pharmacology 28: 166–170, 1989PubMedCrossRefGoogle Scholar
  2. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. Journal of Pediatrics 116: 791–797, 1990PubMedCrossRefGoogle Scholar
  3. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43: 259–284, 1992PubMedCrossRefGoogle Scholar
  4. Blum RA, D’Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Annals of Internal Medicine 114: 755–757, 1991aPubMedGoogle Scholar
  5. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, et al. Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology and Therapeutics 49: 420–425, 1991bPubMedCrossRefGoogle Scholar
  6. Boelaert J, Schurgers M, Matthys E, Daneels R, Van Peer A, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrobial Agents and Chemotherapy 32: 1595–1597, 1988PubMedCrossRefGoogle Scholar
  7. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Reviews of Infectious Diseases 12 (Suppl. 3): S318–S326, 1990PubMedCrossRefGoogle Scholar
  8. Brammer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidosis. Annals of the New York Academy of Sciences 554: 561–563, 1988CrossRefGoogle Scholar
  9. Brasseur P, Bonmarchand G, Caron F, Lecomte F, Leroy J, et al. Diffusion de la 5-fluorocytosine dans les sécrétions bronchiques chez l’insuffisant respiratoire. Annales de Biologie Clinique 45: 685–688, 1987PubMedGoogle Scholar
  10. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51: 1014–1018, 1991PubMedCrossRefGoogle Scholar
  11. Cauwenbergh G. Itraconazole: the first orally active antifungal for single-day treatment of vaginal candidosis. Current Therapeutic Research 41: 210–214, 1987Google Scholar
  12. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. Journal of the American Academy of Dermatology 18: 263–268, 1988PubMedCrossRefGoogle Scholar
  13. Chin T, Fong IW, Vandenbroucke A. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacotherapy 10: 305–307, 1990PubMedGoogle Scholar
  14. Daneshmend TK. Diseases and drugs but not food decrease ketoconazole bioavailability. British Journal of Clinical Pharmacology 29: 783–784, 1990PubMedCrossRefGoogle Scholar
  15. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clinical Pharmacokinetics 8: 17–42, 1983PubMedCrossRefGoogle Scholar
  16. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics 14: 13–34, 1988PubMedCrossRefGoogle Scholar
  17. De Beule K, Lubin G, Cauwenbergh G. Safety aspects of itraconazole therapy in vaginal candidosis, dermatomycosis, and onychomycosis: a review. Current Therapeutic Research 49: 814–822, 1991Google Scholar
  18. Debruyne D, Ryckelynck J-P, Moulin M, Hurault de Ligny B, Levaltier B, et al. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clinical Pharmacokinetics 18: 491–498, 1990PubMedCrossRefGoogle Scholar
  19. Denning DW, Tucker RM, Hanson LH, Stevens DA. Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. Journal of the American Academy of Dermatology 23: 602–607, 1990PubMedCrossRefGoogle Scholar
  20. Drouhet E. Antifungal agents. Antibiotics and Chemotherapy 25: 253–288, 1978PubMedGoogle Scholar
  21. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Archives of Dermatology 106: 344–348, 1972PubMedCrossRefGoogle Scholar
  22. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clinical and Experimental Dermatology 18: 102–106, 1993PubMedCrossRefGoogle Scholar
  23. Faergemann J, Zehender H, Jones T, Maibach HI. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Dermato-Venereologica 71: 322–326, 1991PubMedGoogle Scholar
  24. Finlay AY, Lever L, Thomas R, Dykes PJ. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. Journal of Dermatological Treatment 1 (Suppl. 2): 51–53, 1990CrossRefGoogle Scholar
  25. First MR, Schroeder TJ, Alexander JW, Stephens GW, Weiskittel P, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51: 365–370, 1991PubMedCrossRefGoogle Scholar
  26. Ginsburg CM, McCracken Jr GH, Petruska M, Olsen K. Effect of feeding on bioavailability of griseofulvin in children. Journal of Pediatrics 102: 309–311, 1983PubMedCrossRefGoogle Scholar
  27. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344, 1989PubMedCrossRefGoogle Scholar
  28. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916, 1990PubMedCrossRefGoogle Scholar
  29. Graybill JR. Chemotherapy of systemic mycoses. Seminars in Respiratory Medicine 9: 207–216, 1987CrossRefGoogle Scholar
  30. Hägermark Ö, Berlin A, Wallin I, Boréus LO. Plasma concentrations of griseofulvin in healthy volunteers and out-patients treated for onychomycosis. Acta Dermato-Venereologica 56: 289–296, 1976PubMedGoogle Scholar
  31. Haneke E. Verweildauer von Ketoconazol in der Haut nach oraler Behandlung. Hautarzt 38: 93–96, 1987PubMedGoogle Scholar
  32. Haneke E. Fluconazole levels in human epidermis and blister fluid. British Journal of Dermatology 123: 273–277, 1990PubMedCrossRefGoogle Scholar
  33. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrobial Agents and Chemotherapy 24: 876–882, 1983PubMedCrossRefGoogle Scholar
  34. Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrobial Agents and Chemotherapy 29: 44–48, 1986PubMedCrossRefGoogle Scholar
  35. Hay KD. Candidosis of the oral cavity: recognition and management. Drugs 36: 633–642, 1988PubMedCrossRefGoogle Scholar
  36. Hay RJ. Pharmacokinetic evaluation of fluconazole in skin and nails. International Journal of Dermatology 31 (Suppl. 2): 6–7, 1992Google Scholar
  37. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23: 1–36, 1982PubMedCrossRefGoogle Scholar
  38. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, et al. The pharmacokinetics of itraconazole in animals and man: an overview. In Fromtling (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents, pp. 223–249, Prous Science Publishers, Barcelona, 1987Google Scholar
  39. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32 (Suppl. 1): 67–87, 1989PubMedGoogle Scholar
  40. Houang ET, Chappatte O, Byrne D, MacRae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrobial Agents and Chemotherapy 34: 909–910, 1990PubMedCrossRefGoogle Scholar
  41. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 28: 648–653, 1985PubMedCrossRefGoogle Scholar
  42. Ittel TH, Legier UF, Polak A, Glöckner WM, Sieberth HG. 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration. Chemotherapy 33: 77–84, 1987PubMedCrossRefGoogle Scholar
  43. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clinical and Experimental Dermatology 14: 110–113, 1989PubMedCrossRefGoogle Scholar
  44. Jensen JC. Pharmacokinetics of Lamisil® in humans. Journal of Dermatological Treatment 1 (Suppl. 2): 15–18, 1990CrossRefGoogle Scholar
  45. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? a review three decades after griseofulvin. Archives of Dermatology 128: 243–248, 1992PubMedCrossRefGoogle Scholar
  46. Korting HC, Lukacs A, Schäfer-Korting M. Skin blister fluid levels of ketoconazole during repetitive administration in man. Mycoses 32: 39–45, 1989PubMedCrossRefGoogle Scholar
  47. Kowalsky SF. Drug interactions with fluconazole. Pharmacotherapy 10 (Suppl.): 170S–173S, 1990PubMedGoogle Scholar
  48. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Annals of Internal Medicine 113: 327–329, 1990PubMedGoogle Scholar
  49. Lachapelle JM, De Doncker P, Tennstedt D, Cauwenbergh G, Janssen PAJ. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 184: 45–50, 1992PubMedCrossRefGoogle Scholar
  50. Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, et al. Gastropathy and ketoconazole malabsorption in the acquired immuno-deficiency syndrome (AIDS). Annals of Internal Medicine 109: 471–473, 1988PubMedGoogle Scholar
  51. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. British Medical Journal 294: 419–420, 1987PubMedCrossRefGoogle Scholar
  52. Lazar JD, Wilner KD. Drug interactions with fluconazole. Reviews of Infectious Diseases 12 (Suppl. 3): S327–S333, 1990PubMedCrossRefGoogle Scholar
  53. Lever LR, Dykes PJ, Thomas R, Finlay AY. How orally administered terbinafine reaches the stratum corneum. Journal of Dermatological Treatment 1 (Suppl. 2): 23–25, 1990CrossRefGoogle Scholar
  54. Lin C, Lim J, DiGiore C, Gural R, Symchowicz S. Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man. Journal of International Medical Research 20: 274–277, 1982Google Scholar
  55. Lin C, Symchowicz S. Absorption, distribution, metabolism, and excretion of griseofulvin in man and animals. Drug Metabolism Reviews 41: 75–95, 1975CrossRefGoogle Scholar
  56. Machard B, Misslin P, Lemaire M. Influence of plasma protein binding on the brain uptake of an antifungal agent, terbinafine, in rats. Journal of Pharmacy and Pharmacology 41: 700–704, 1989PubMedCrossRefGoogle Scholar
  57. Malet-Martino MC, Martino M, de Forni M, Andremont A, Hartmann O, et al. Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection 19: 178–180, 1991PubMedCrossRefGoogle Scholar
  58. Matthieu L, De Doncker P, Cauwenbergh G, Woestenborghs R, Van de Velde V, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed — an investigation in onychomycosis. Clinical and Experimental Dermatology 16: 374–376, 1991PubMedCrossRefGoogle Scholar
  59. McNulty RM, Lazor JA, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. Clinical Pharmacy 8: 222–225, 1989PubMedGoogle Scholar
  60. Milliken S, Helenglass G, Powles R. Fluconazole pharmacokinetics following oral dosage in leukaemic patients receiving autologous bone marrow transplantation. Bone Marrow Transplantation 3: 324–325, 1988Google Scholar
  61. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, et al. Torsades des pointes occurring in association with terfenadine use. Journal of the American Medical Association 264: 2788–2790, 1990PubMedCrossRefGoogle Scholar
  62. Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. Journal of Antimicrobial Chemotherapy 16: 81–86, 1985PubMedCrossRefGoogle Scholar
  63. Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrobial Agents and Chemotherapy 29: 579–583, 1986PubMedCrossRefGoogle Scholar
  64. Piérard GE, Rurangirwa A, Piérard-Franchimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clinical and Experimental Dermatology 16: 168–171, 1991PubMedCrossRefGoogle Scholar
  65. Piscitelli SC, Goss TF, Wilton JH, D’Andrea DT, Goldstein H, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrobial Agents and Chemotherapy 35: 1765–1771, 1991PubMedCrossRefGoogle Scholar
  66. Polak A. Pharmacokinetics of amphotericin B and flucytosine. Postgraduate Medical Journal 55: 667–670, 1979PubMedCrossRefGoogle Scholar
  67. Ritter W. Pharmacokinetics of azole compounds. In Berg & Plempel (Eds) Sterol biosynthesis inhibitors, pp. 397–429, Ellis Horwood, Chichester, 1988Google Scholar
  68. Schäfer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A. Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrobial Agents and Chemotherapy 35: 2053–2056, 1991PubMedCrossRefGoogle Scholar
  69. Schäfer-Korting M, Korting HC, Dorn M, Mutschier E. Ketoconazole concentrations in human skin blister fluid and plasma. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 371–374, 1984Google Scholar
  70. Schäfer-Korting M, Korting HC, Lukacs A, Heykants J, Behrendt H. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. Journal of the American Academy of Dermatology 22: 211–215, 1990PubMedCrossRefGoogle Scholar
  71. Schäfer-Korting M, Korting HC, Mutschier E. Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. European Journal of Clinical Pharmacology 29: 109–113, 1985aPubMedCrossRefGoogle Scholar
  72. Schäfer-Korting M, Korting HC, Mutschier E. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. European Journal of Clinical Pharmacology 29: 351–354, 1985bPubMedCrossRefGoogle Scholar
  73. Schuster I, Schaude M, Schatz F, Mieth H. Preclinical aspects of allylamines. In Berg & Plempel (Eds) Sterol biosynthesis inhibitors, pp. 449–470, Ellis Horwood, Chichester, 1988Google Scholar
  74. Shiba K, Saito A, Miyahara T. Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clinical Therapeutics 12: 206–215, 1990PubMedGoogle Scholar
  75. Sobel JD. Individualizing treatment of vaginal candidiasis. Journal of the American Academy of Dermatology 23: 572–576, 1990PubMedCrossRefGoogle Scholar
  76. Stein AG, Daneshmend TK, Warnock DW, Bhaskar N, Burke J, et al. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. British Journal of Clinical Pharmacology 27: 105P–106P, 1989Google Scholar
  77. Terhaag B, Pachaly C, Frank G, Le Petit G, Feller K. Zur Entwicklung des Steady-state-Plasma-Spiegels von Griseofulvin nach wiederholter Gabe beim Menschen. Zeitschrift für Klinische Medizin 41: 1371–1374, 1986Google Scholar
  78. Torregrosa V, De la Torre M, Campistol JM, Oppenheimer F, Ricart MJ, et al. Interaction of fluconazole with cyclosporine A. Nephron 60: 125–126, 1992PubMedCrossRefGoogle Scholar
  79. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Reviews of Infectious Diseases 9 (Suppl. 1): S94–S99, 1987PubMedGoogle Scholar
  80. Tucker RM, Denninng DW, Hanson LH, Rinaldi MG, Graybill JR, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clinics in Infectious Diseases 14: 165–174, 1992CrossRefGoogle Scholar
  81. Tucker RM, Williams PL, Arathoon EG, Levine BE, Hartstein AI, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrobial Agents and Chemotherapy 32: 369–373, 1988PubMedCrossRefGoogle Scholar
  82. Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Cauwenbergh G. The effect of food and dose on the oral systemic availability of itraconazole in healthy subjects. European Journal of Clinical Pharmacology 36: 423–426, 1989PubMedCrossRefGoogle Scholar
  83. Van’t Wout JW, de Graeff-Meeder ER, Paul LC, Kuis W, Van Furth R. Treatment of two cases of cryptococcal meningitis with fluconazole. Scandinavian Journal of Infectious Disease 20: 193–198, 1988CrossRefGoogle Scholar
  84. Vialaneix JP, Malet-Martino MC, Hoffmann JS, Pris J, Martino R. Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance. Drug Metabolism and Disposition 15: 718–724, 1987PubMedGoogle Scholar
  85. Wells C, Lever AML. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. Journal of Infection 24: 111–112, 1992PubMedCrossRefGoogle Scholar
  86. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, et al. Post-treatment itraconazole levels in the nail: new implications for treatment of onychomycosis. Journal of the American Academy of Dermatology 26: 731–735, 1992PubMedCrossRefGoogle Scholar
  87. Yamashita SK, Ludwig EA, Middleton Jr E, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clinical Pharmacology and Therapeutics 49: 558–570, 1991PubMedCrossRefGoogle Scholar
  88. Zürcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clinical Pharmacology and Therapeutics 45: 366–372, 1989PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Monika Schäfer-Korting
    • 1
  1. 1.Institut für Pharmazie der Freien Universität BerlinBerlinFederal Republic of Germany

Personalised recommendations